The novelty of the present study lies in the fact that no previous work has been cited in the literature on repurposing cyclooxygenase-2 (COX-2) inhibitor etoricoxib and formulated into nanoemulsion formulation for improving anticancer activities against lung cancer cells. This evidence concerns the gene PTGS2 and lung carcinoma.